{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T08:01:19Z","timestamp":1762675279775,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012238","name":"Frederick Gardner Cottrell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012238","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118196","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:51:43Z","timestamp":1758941503000},"page":"118196","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Synthesis, SAR, and biophysical mechanism of action of cyclopropabenzindole-pyridinobenzodiazepine (CBI-PDD) guanine-adenine DNA cross-linking agents"],"prefix":"10.1016","volume":"301","author":[{"given":"George","family":"Procopiou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.M.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniella","family":"di Mascio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"Auer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Andriollo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilona","family":"Pysz-Hosey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Mantaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khondaker Miraz","family":"Rahman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith R.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8032-7203","authenticated-orcid":false,"given":"David E.","family":"Thurston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ejmech.2025.118196_bib1","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/anie.201510610","article-title":"From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody\u2013drug conjugates (ADCs)","volume":"56","author":"Mantaj","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2025.118196_bib2","series-title":"Cytotoxic Payloads for Antibody \u2013 Drug Conjugates","article-title":"Duocarmycins as antibody\u2013drug conjugate (ADC) payloads","author":"Beekman","year":"2019"},{"issue":"24","key":"10.1016\/j.ejmech.2025.118196_bib3","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1021\/ja00952a050","article-title":"Isolation and characterization of anthramycin, a new antitumor antibiotic","volume":"87","author":"Leimgruber","year":"1965","journal-title":"J. Am. Chem. Soc."},{"issue":"12","key":"10.1016\/j.ejmech.2025.118196_bib4","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.7164\/antibiotics.31.1211","article-title":"CC-1065 (NSC-298223), a new antitumor antibiotic. Production, in vitro biological activity, microbiological assays and taxonomy of the producing microorganism","volume":"31","author":"Hanka","year":"1978","journal-title":"J. Antibiot. (Tokyo)"},{"issue":"6","key":"10.1016\/j.ejmech.2025.118196_bib5","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3390\/cancers17060958","article-title":"Opportunities and challenges in antibody\u2013drug conjugates for cancer therapy: a new era for cancer treatment","volume":"17","author":"Buyukgolcigezli","year":"2025","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118196_bib6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00280-009-1088-4","article-title":"A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors","volume":"65","author":"Janjigian","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118196_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","article-title":"A review of the clinical efficacy of FDA-Approved antibody\u2012drug conjugates in human cancers","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"13","key":"10.1016\/j.ejmech.2025.118196_bib8","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1093\/nar\/gkr122","article-title":"Effect of base sequence on the DNA cross-linking properties of pyrrolobenzodiazepine (PBD) dimers","volume":"39","author":"Rahman","year":"2011","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118196_bib9","first-page":"8","article-title":"Transcription factor inhibition as a potential additional mechanism of action of pyrrolobenzodiazepine (PBD) dimers","volume":"5","author":"Mantaj","year":"2025","journal-title":"DNA (N. Y.)"},{"issue":"11","key":"10.1016\/j.ejmech.2025.118196_bib10","first-page":"814","article-title":"Cancer stem cell candidate Rova-T discontinued","volume":"18","author":"Mullard","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118196_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221087511","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data","volume":"13","author":"Furqan","year":"2022","journal-title":"Therapeutic Advances in Hematology"},{"issue":"9","key":"10.1016\/j.ejmech.2025.118196_bib12","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1073\/pnas.92.9.3642","article-title":"CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents","volume":"92","author":"Boger","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.118196_bib13","series-title":"Cytotoxic Payloads for Antibody \u2013 Drug Conjugates","article-title":"CXI dimers as antibody\u2013drug conjugate (ADC) payloads","author":"Procopiou","year":"2019"},{"issue":"5","key":"10.1016\/j.ejmech.2025.118196_bib14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/annonc\/mdg215","article-title":"A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies","volume":"14","author":"Schwartz","year":"2003","journal-title":"Ann. Oncol."},{"issue":"35","key":"10.1016\/j.ejmech.2025.118196_bib15","doi-asserted-by":"crossref","first-page":"11005","DOI":"10.1021\/bi00035a006","article-title":"Determination of the structural role of the internal guanine-cytosine base pair in recognition of a seven-base-pair sequence cross-linked by bizelesin","volume":"34","author":"Thompson","year":"1995","journal-title":"Biochemistry"},{"issue":"15_suppl","key":"10.1016\/j.ejmech.2025.118196_bib16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.1014","article-title":"A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer","volume":"36","author":"Saura","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118196_bib17","series-title":"Cytotoxic Payloads for Antibody \u2013 Drug Conjugates","article-title":"Duocarmycin\u2013PBD dimers as antibody\u2013drug conjugate (ADC) payloads","author":"Pillow","year":"2019"},{"issue":"20","key":"10.1016\/j.ejmech.2025.118196_bib18","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1021\/ja005658r","article-title":"Design and synthesis of a novel DNA\u2212DNA interstrand adenine\u2212guanine cross-linking agent","volume":"123","author":"Zhou","year":"2001","journal-title":"J. Am. Chem. Soc."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118196_bib19","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1021\/jm020526p","article-title":"Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores","volume":"46","author":"Tercel","year":"2003","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118196_bib20","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s42003-022-03633-0","article-title":"DNA sequence-selective G-A cross-linking ADC payloads for use in solid tumour therapies","volume":"5","author":"Procopiou","year":"2022","journal-title":"Commun. Biol."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118196_bib21","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1021\/jm301882a","article-title":"GC-Targeted C8-Linked pyrrolobenzodiazepine\u2013biaryl conjugates with femtomolar in vitro cytotoxicity and in vivo antitumor activity in mouse models","volume":"56","author":"Rahman","year":"2013","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.ejmech.2025.118196_bib22","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1021\/jm9006214","article-title":"Fundamental relationships between structure, reactivity, and biological activity for the duocarmycins and CC-1065","volume":"52","author":"MacMillan","year":"2009","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2025.118196_bib23","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1021\/jo035465x","article-title":"Effective asymmetric synthesis of 1,2,9,9a-Tetrahydrocyclopropa[c]benzo[e]indol-4-one (CBI)","volume":"69","author":"Kastrinsky","year":"2004","journal-title":"J. Org. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118196_bib24","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/0968-0896(95)00130-9","article-title":"1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) analogs of CC-1065 and the duocarmycins: synthesis and evaluation","volume":"3","author":"Boger","year":"1995","journal-title":"Bioorg. Med. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2025.118196_bib25","doi-asserted-by":"crossref","first-page":"7854","DOI":"10.1016\/j.bmc.2006.07.062","article-title":"Synthesis and antitumor activity of CBI-bearing ester and carbamate prodrugs of CC-1065 analogue","volume":"14","author":"Wang","year":"2006","journal-title":"Bioorg. Med. Chem."},{"issue":"20","key":"10.1016\/j.ejmech.2025.118196_bib26","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1039\/c39920001518","article-title":"Effect of linker length on DNA-Binding affinity, cross-linking efficiency and cytotoxicity of C8-linked pyrrolobenzodiazepine dimers","author":"Bose","year":"1992","journal-title":"J. Chem. Soc., Chem. Commun."},{"issue":"2","key":"10.1016\/j.ejmech.2025.118196_bib27","doi-asserted-by":"crossref","DOI":"10.1042\/bst023331s","article-title":"The cytotoxicity of anthramycin to mutants of Schizosaccharomyces pombe deficient in DNA damage responses","volume":"23","author":"Hafiz","year":"1995","journal-title":"Biochem. Soc. Trans."},{"issue":"3","key":"10.1016\/j.ejmech.2025.118196_bib28","first-page":"999","article-title":"CC-1065 (NSC 298223), a novel antitumor agent that interacts strongly with double-stranded DNA","volume":"42","author":"Li","year":"1982","journal-title":"Cancer Res."},{"issue":"31","key":"10.1016\/j.ejmech.2025.118196_bib29","doi-asserted-by":"crossref","first-page":"9317","DOI":"10.1021\/bi000748u","article-title":"Binding of distamycin A and netropsin to the 12mer DNA duplexes containing mixed AT\u00b7GC sequences with at Most five or three successive AT base pairs","volume":"39","author":"Lah","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.118196_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jphotobiol.2012.07.003","article-title":"Chemistry of DNA minor groove binding agents","volume":"115","author":"Khan","year":"2012","journal-title":"J. Photochem. Photobiol., B"},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2025.118196_bib31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1023\/A:1006898812618","article-title":"The anti-cancer agent distamycin A displaces essential transcription factors and selectively inhibits myogenic differentiation","volume":"169","author":"Taylor","year":"1997","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejmech.2025.118196_bib32","first-page":"131","article-title":"Chapter six - imine reductases, reductive aminases, and amine oxidases for the synthesis of chiral amines: discovery, characterization, and synthetic applications","volume":"608","author":"Cosgrove","year":"2018"},{"issue":"1","key":"10.1016\/j.ejmech.2025.118196_bib33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cctc.201500822","article-title":"Combined imine reductase and amine oxidase catalyzed deracemization of nitrogen heterocycles","volume":"8","author":"Heath","year":"2016","journal-title":"ChemCatChem"},{"issue":"3","key":"10.1016\/j.ejmech.2025.118196_bib34","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","article-title":"Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody\u2013drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study","volume":"25","author":"Daver","year":"2024","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.118196_bib35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0003-2697(91)90052-U","article-title":"An agarose gel method for the determination of DNA interstrand crosslinking applicable to the measurement of the rate of total and \u201csecond-arm\u201d crosslink reactions","volume":"193","author":"Hartley","year":"1991","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejmech.2025.118196_bib36","series-title":"Drug-DNA Interaction Protocols","first-page":"219","article-title":"Evaluation of drug-nucleic acid interactions by thermal melting curves","author":"David Wilson","year":"1997"},{"issue":"2","key":"10.1016\/j.ejmech.2025.118196_bib37","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1006\/abio.2001.5124","article-title":"Preferred binding sites for [N-MeCys3,N-MeCys7]TANDEM determined using a universal footprinting substrate","volume":"293","author":"Lavesa","year":"2001","journal-title":"Anal. Biochem."},{"issue":"11","key":"10.1016\/j.ejmech.2025.118196_bib38","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1021\/acsmedchemlett.6b00062","article-title":"Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload","volume":"7","author":"Tiberghien","year":"2016","journal-title":"ACS Med. Chem. Lett."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:58:55Z","timestamp":1762675135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"alternative-id":["S0223523425009614"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118196","relation":{},"ISSN":["0223-5234"],"issn-type":[{"type":"print","value":"0223-5234"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis, SAR, and biophysical mechanism of action of cyclopropabenzindole-pyridinobenzodiazepine (CBI-PDD) guanine-adenine DNA cross-linking agents","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118196","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118196"}}